Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Therapeutics, Genmab to Develop Antibody Tx

NEW YORK, April 11 - Genmab and Paradigm Therapeutics today said they plan to co-develop new antibody therapeutics.

The partners will combine Paradigm's disease targets and bioinformatics platform with Genmab's fully human antibody technology to develop therapeutics for cancer, inflammatory diseases, and other states.

Genmab and Paradigm will share development costs along with any revenue that may come from out-licensing or selling potential products. Financial details were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.